Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 20 studies | 57% ± 21% | |
lung | 16 studies | 52% ± 17% | |
intestine | 11 studies | 51% ± 25% | |
kidney | 7 studies | 52% ± 15% | |
eye | 7 studies | 38% ± 18% | |
bone marrow | 6 studies | 44% ± 19% | |
lymph node | 5 studies | 63% ± 9% | |
brain | 5 studies | 33% ± 10% | |
liver | 5 studies | 53% ± 22% | |
placenta | 4 studies | 47% ± 21% | |
uterus | 4 studies | 67% ± 5% | |
breast | 4 studies | 66% ± 15% | |
pancreas | 3 studies | 55% ± 19% | |
prostate | 3 studies | 75% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 23306.46 | 653 / 653 | 100% | 296.93 | 605 / 605 |
uterus | 100% | 36904.81 | 170 / 170 | 100% | 179.02 | 457 / 459 |
ovary | 100% | 52337.33 | 180 / 180 | 100% | 142.81 | 428 / 430 |
pancreas | 100% | 33977.41 | 328 / 328 | 99% | 207.03 | 177 / 178 |
kidney | 100% | 15429.91 | 89 / 89 | 99% | 187.11 | 895 / 901 |
prostate | 100% | 29297.31 | 245 / 245 | 99% | 326.20 | 498 / 502 |
esophagus | 100% | 22965.46 | 1445 / 1445 | 99% | 93.33 | 181 / 183 |
skin | 99% | 33891.10 | 1799 / 1809 | 99% | 205.38 | 469 / 472 |
adrenal gland | 100% | 15517.51 | 258 / 258 | 99% | 170.08 | 227 / 230 |
stomach | 100% | 22481.70 | 359 / 359 | 99% | 165.74 | 282 / 286 |
intestine | 100% | 26803.86 | 966 / 966 | 98% | 196.38 | 518 / 527 |
bladder | 100% | 29133.29 | 21 / 21 | 98% | 188.72 | 495 / 504 |
lung | 99% | 16523.81 | 573 / 578 | 98% | 125.32 | 1134 / 1155 |
breast | 100% | 31771.38 | 459 / 459 | 97% | 161.59 | 1083 / 1118 |
brain | 93% | 6957.95 | 2450 / 2642 | 100% | 129.66 | 702 / 705 |
liver | 92% | 7780.57 | 208 / 226 | 99% | 140.16 | 403 / 406 |
adipose | 100% | 27644.48 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 618.87 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 438.16 | 29 / 29 |
spleen | 100% | 25506.20 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 174.27 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 91.83 | 1 / 1 |
blood vessel | 100% | 21346.39 | 1334 / 1335 | 0% | 0 | 0 / 0 |
muscle | 99% | 12202.14 | 791 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 97% | 19381.33 | 900 / 929 | 0% | 0 | 0 / 0 |
heart | 96% | 11015.69 | 830 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006281 | Biological process | DNA repair |
GO_1902570 | Biological process | protein localization to nucleolus |
GO_0032435 | Biological process | negative regulation of proteasomal ubiquitin-dependent protein catabolic process |
GO_0032436 | Biological process | positive regulation of proteasomal ubiquitin-dependent protein catabolic process |
GO_0006974 | Biological process | DNA damage response |
GO_0031333 | Biological process | negative regulation of protein-containing complex assembly |
GO_0000027 | Biological process | ribosomal large subunit assembly |
GO_0001932 | Biological process | regulation of protein phosphorylation |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_1903006 | Biological process | positive regulation of protein K63-linked deubiquitination |
GO_0051898 | Biological process | negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
GO_0007095 | Biological process | mitotic G2 DNA damage checkpoint signaling |
GO_0039535 | Biological process | regulation of RIG-I signaling pathway |
GO_0042981 | Biological process | regulation of apoptotic process |
GO_1901837 | Biological process | negative regulation of transcription of nucleolar large rRNA by RNA polymerase I |
GO_0050821 | Biological process | protein stabilization |
GO_1901796 | Biological process | regulation of signal transduction by p53 class mediator |
GO_1903715 | Biological process | regulation of aerobic respiration |
GO_1990173 | Biological process | protein localization to nucleoplasm |
GO_0006364 | Biological process | rRNA processing |
GO_0051726 | Biological process | regulation of cell cycle |
GO_1901797 | Biological process | negative regulation of signal transduction by p53 class mediator |
GO_0071456 | Biological process | cellular response to hypoxia |
GO_0005730 | Cellular component | nucleolus |
GO_0005654 | Cellular component | nucleoplasm |
GO_0001650 | Cellular component | fibrillar center |
GO_0005829 | Cellular component | cytosol |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0033553 | Cellular component | rDNA heterochromatin |
GO_0042802 | Molecular function | identical protein binding |
GO_0008097 | Molecular function | 5S rRNA binding |
GO_0002039 | Molecular function | p53 binding |
GO_0003723 | Molecular function | RNA binding |
GO_0005515 | Molecular function | protein binding |
Gene name | NOP53 |
Protein name | Ribosome biogenesis protein NOP53 (Glioma tumor suppressor candidate region gene 2 protein) (Protein interacting with carboxyl terminus 1) (PICT-1) (p60) Ribosome biogenesis protein NOP53 |
Synonyms | GLTSCR2 PICT1 GLT |
Description | FUNCTION: Nucleolar protein which is involved in the integration of the 5S RNP into the ribosomal large subunit during ribosome biogenesis . In ribosome biogenesis, may also play a role in rRNA transcription . Also functions as a nucleolar sensor that regulates the activation of p53/TP53 in response to ribosome biogenesis perturbation, DNA damage and other stress conditions . DNA damage or perturbation of ribosome biogenesis disrupt the interaction between NOP53 and RPL11 allowing RPL11 transport to the nucleoplasm where it can inhibit MDM2 and allow p53/TP53 activation . It may also positively regulate the function of p53/TP53 in cell cycle arrest and apoptosis through direct interaction, preventing its MDM2-dependent ubiquitin-mediated proteasomal degradation . Originally identified as a tumor suppressor, it may also play a role in cell proliferation and apoptosis by positively regulating the stability of PTEN, thereby antagonizing the PI3K-AKT/PKB signaling pathway . May also inhibit cell proliferation and increase apoptosis through its interaction with NF2 . May negatively regulate NPM1 by regulating its nucleoplasmic localization, oligomerization and ubiquitin-mediated proteasomal degradation . Thereby, may prevent NPM1 interaction with MYC and negatively regulate transcription mediated by the MYC-NPM1 complex . May also regulate cellular aerobic respiration . In the cellular response to viral infection, may play a role in the attenuation of interferon-beta through the inhibition of RIGI . . |
Accessions | ENST00000597985.5 M0QZ34 M0QZU5 ENST00000246802.10 Q96CS0 M0QYZ9 Q9NZM5 ENST00000598959.5 ENST00000595143.5 ENST00000594182.1 M0QX73 |